CRH Medical (TSX: CRH), the Healthcare company, has received a rating update from a Wall Street analyst today. The company received a Buy rating from Clarus’ analyst Noel Atkinson.
Atkinson has an average return of 27.9% when recommending CRH Medical.
According to TipRanks.com, Atkinson is ranked #104 out of 4849 analysts.
Read also: Here’s Why Bellerophon’s (BLPH) Stock Collapsed Today
CRH Medical has an analyst consensus of Strong Buy, with a price target consensus of C$5.25, which is a 16.7% upside from current levels. In a report issued on July 27, TD Securities also upgraded the stock to Buy with a C$5 price target.
.
The company has a one-year high of C$4.76 and a one-year low of C$1.86. Currently, CRH Medical has an average volume of 153.4K.
CRH Medical Corp. engages in the provision of gastroenterologists with innovative services and products for the treatment of gastrointestinal diseases. It offers CRH O’Regan System, which focuses on physician education, patient outcomes, and patient awareness. The company was founded in 2000 and is headquartered in Vancouver, Canada.
The company’s shares closed on Tuesday at C$4.50, close to its 52-week high of C$4.76.
